These guidelines form a constituent part of Chapter 22 (haemopoietic progenitor cells) of the Guidelines for the Blood Transfusion Services in the United Kingdom, 8th Edition, 2013.
The criteria are reviewed regularly to ensure that the stem cells obtained are of the highest quality and of sufficient quantity to meet the needs of recipients.
The Joint Professional Advisory committee (JPAC) of the UKBTS is responsible for this document. JPAC receives professional advice from the Standing Advisory Committees (SACs) that form part of its structure and from other relevant expert groups.
Users of these guidelines must ensure that they have the latest version and that recent changes have been implemented (usually within three months) by their national service.
Latest Updates lists alterations to the guidelines made since publication of this edition.
Advice on these guidelines can be obtained from:
Dr L Williamson, Medical and Research Director
National Health Service Blood & Transplant (NHSBT)
Prof M Turner, Medical & Scientific Director
Scottish National Blood Transfusion Service (SNBTS)
Dr SP Field, Medical Director
Welsh Blood Service (WBS)
Dr K Morris, Medical Chief Executive Officer
Northern Ireland Blood Transfusion Service (NIBTS)
Comments about the content of these guidelines, including notification of errors, omissions and suggestions for improvements, should be sent to the Chair of SAC-Tissues and Cellular Therapy Products:
Dr Akila Chandrasekar
NHSBT Tissue Services
14 Estuary Bank
Preferably by e-mail to firstname.lastname@example.org with TDSG-BM in the subject line.
This section was last updated in TDSG-BM Edition 203, Release 17 Issue 01